Axi-cel CAR-T therapy extends EFS in patients with R/R large B-cell lymphoma

  • The randomised phase 3 trial included 359 patients that were randomly assigned a single fusion of axi-cel or standard-of-care therapies for R/R large B-cell lymphoma
  • Results showed a significant EFS improvement (HR = 0.39; P<0.0001) among patients assigned axi-cel
  • Axi-cel also exhibited a safety profile consistent with that observed with use of the agent in the third-line setting

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

ref: JUL2021CW001